LoginSignup
Krystal Biotech logo

Krystal Biotech

Stock
Stock
ISIN: US5011471027
Ticker: KRYS
US5011471027
KRYS

Price

Price

Frequently asked questions

What is Krystal Biotech's market capitalization?

The market capitalization of Krystal Biotech is $5.24B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Krystal Biotech's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Krystal Biotech is 103.14. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Krystal Biotech?

Krystal Biotech's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $1.767. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Krystal Biotech's stock?

Currently, 10 analysts cover Krystal Biotech's stock, with a consensus target price of $189.00. Analyst ratings provide insights into the stock's expected performance.

What is Krystal Biotech's revenue over the trailing twelve months?

Over the trailing twelve months, Krystal Biotech reported a revenue of $241.52M.

What is the EBITDA for Krystal Biotech?

Krystal Biotech's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $71.99M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Krystal Biotech?

Krystal Biotech has a free cash flow of $58.06M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Krystal Biotech's stock?

The 5-year beta for Krystal Biotech is 0.78. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Krystal Biotech have, and what sector and industry does it belong to?

Krystal Biotech employs approximately 229 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Krystal Biotech's shares?

The free float of Krystal Biotech is 25.22M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $5.24B

5Y beta

 0.78

EPS (TTM)

 $1.767

Free Float

 25.22M

P/E ratio (TTM)

 103.14

Revenue (TTM)

 $241.52M

EBITDA (TTM)

 $71.99M

Free Cashflow (TTM)

 $58.06M

Pricing

1D span
$181.67$185.79
52W span
$99.00$219.34

Analyst Ratings

The price target is $189.00 and the stock is covered by 10 analysts.

Buy

9

Hold

1

Sell

0

Information

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patient’s skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.

229

Biotechnology & Drugs

Health Care

Identifier

ISIN

US5011471027

Primary Ticker

KRYS

Knockouts

Join the conversation
Sign upLogin